Covaxin, a whole-virion inactivated coronavirus vaccine, is the first and only product to have published any data from human clinical trial...

Earlier in the week, NITI Aayog's Member Health, Dr V.K. Paul said: "Covaxin has been approved by the Drugs Controller General of India (DC...

The efficacy of the jab can be improved upto 100 per cent protection by the COVID-19 appropriate behaviour and following other safety proto...

Covaxin, which has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is be...

After more than two hours of deliberation on Wednesday, the SEC in its recommendation to the drug regulator asked for the removal of clinic...

The vaccine was granted approval “for restricted use in emergency situation in public interest as an abundant precaution, in clinical trial...

Speaking to ET, Punjab health minister Balbir Singh Sidhu said: “We don’t want to deploy the vaccine right away. Our expert panel of doctor...

Covaxin is India's totally indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and National ...

In the letters addressed to the PM and Union Health Minister Harsh Vardhan, these NGOs have also sought punishment for the "responsible par...

Hyderabad-based vaccine manufacturer Bharat Biotech has concluded the recruitment of volunteers for the phase III trials of its Covid vacci...

The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers and it is the countrys first an...

"COVAXIN clinical trials are based on a two-dose schedule, given 28 days apart. The vaccine efficacy will be determined 14 days after the s...

"I will be administered a trial dose of Coronavirus vaccine #Covaxin a Bharat Biotech product Tomorrow at 11 am at Civil hospital, Ambala C...

Bharat Biotech had on Monday said the Phase 3 trial of Covaxin will involve 26,000 volunteers across 25 centres in India and is being condu...

Hyderabad-based Bharat Biotech is considering expanding phase-III trial of its Covid-19 vaccine candidate Covaxin by adding more sites to t...

The regulator’s subject expert committee met on Tuesday and approved the phase-3 trial of the company’s indigenously developed vaccine cand...

Human trials of Covaxin, India's first vaccine candidate against coronavirus, began at PGI Rohtak on July 17. Three volunteers were adminis...